INTRODUCTION {#s5}
============

Polymyositis (PM) and dermatomyositis (DM) are idiopathic inflammatory myopathies that affect skeletal muscle, skin, joints and lungs to various degrees.^[@R1]^ Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with PM/DM.^[@R2]^ The aetiology of PM/DM still remains unknown, but it is believed that the disease occurs as a result of exposure to environmental factors in genetically susceptible individuals.^[@R3]^ The infection of microorganisms is known as an environmental trigger. For instance, a Swedish case--control study reported preceding infection as a risk factor for PM/DM.^[@R4]^ Another report demonstrated an increased prevalence of anti-Coxsackie B virus antibodies in patients with juvenile DM.^[@R5]^ In addition, there are several studies showing seasonal associations and spatial clustering of PM/DM onset in the disease subsets defined by myositis-specific autoantibodies (MSAs). Namely, seasonal patterns of PM/DM onset were different between patients with anti-Jo-1 antibody and those with anti-signal recognition particle antibody.^[@R6]^ Interestingly, the seasonal influence on disease onset in patients positive for anti-aminoacyl-tRNA synthetase (anti-ARS) antibodies, including anti-Jo-1, was different between African and non-African patients.^[@R7]^

Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is an MSA associated with rapidly progressive ILD, which often leads to fatal outcomes.^[@R8]^ Since MDA5 is a pattern recognition protein that works as a sensor for viral RNA,^[@R10]^ the autoimmune response to MDA5 might emerge as a consequence of the preceding infection of specific viruses. In this regard, a single-centre study reported that the majority of anti-MDA5 antibody-positive patients resided outside of urban areas and around a large river.^[@R11]^ To further explore the potential roles of environmental factors in the development of PM/DM-associated ILD in the context of MSAs, we examined seasonal and geographical influences on disease onset by taking advantage of the use of a multicentre retrospective Japanese Patients with Myositis-associated ILD (JAMI) cohort that involved 499 incident cases of PM-/DM-associated ILD.^[@R12]^

METHODS {#s6}
=======

Patients {#s6-s1}
--------

The JAMI cohort enrolled adult incident patients with PM, classic DM or clinically amyopathic DM (CADM) who had ILD at diagnosis (UMIN000018663).^[@R12]^ Incident PM-/DM-associated ILD cases who visited their centres between October 2011 and October 2015 were enrolled. Forty-four JAMI participating centres are located across Japan, but there is a cluster in the Greater Tokyo region, serving about one-third of the national population ([online supplemental figure 1](#SP1){ref-type="supplementary-material"}). All centres were located in large cities, which are built around major rivers. Information on disease onset was carefully collected from individual patients by detailed history taking. The time (month, year) of onset was defined when any clinical signs or symptoms suggestive of PM/DM were first observed by the patients. Initial symptoms were classified into skin eruption (ie, specific and non-specific skin lesions with or without itch), respiratory symptoms (ie, cough and dyspnoea), fever, arthralgia, muscle symptoms (ie, weakness and myalgia) and others. Anti-MDA5 and anti-ARS antibodies were measured centrally using ELISA^[@R13]^ and RNA immunoprecipitation assay, respectively.

![Seasonality analysis. Rose diagrams of the Rayleigh test showing the number of patients categorised by months of disease onset. The radius of each sector of the circle indicates the number of patients. Inside and outside circles represent 10 and 20 cases, respectively. An arrow indicates the mean direction of the circular data for significant seasonality. (A) Anti-MDA5-positive patients. (B) Anti-ARS-positive patients. Black sectors indicate numbers of patients with anti-Jo-1 antibody. (C) Anti-MDA5-/ARS-negative patients.\
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Seasonal analysis {#s6-s2}
-----------------

The month of disease onset was analysed by the Rayleigh test, which handles circular data for testing uniformity.^[@R14]^ If the *p* value was \<0.05, the null hypothesis where the incidence was uniform across the year was rejected, and disease onset had unimodal distribution, showing seasonality. To reduce the effects of small sample years, we included only patients who developed the disease within the last 5 years.

Geographical analysis {#s6-s3}
---------------------

The JAMI database collected the postal code of the patient's residence at the time of disease onset. We entered postal codes into the 'My Map' application of Google Map (Google, Mountain View, CA, USA, in collaboration with ZENRIN, Kitakyushu, Japan) and then measured the shortest straight-line distance from the postal code marker to the nearest waterfront, which was defined as any river, lake, pond or sea identifiable on Google Map on maximum enlargement. The only exclusion was small streams or ponds, which are not included in the river/lake list made by local governments. A representative map showing rivers, lakes, ponds and sea in the Tokyo--Yokohama area is shown in [online supplemental figure 2](#SP1){ref-type="supplementary-material"}. In some analyses, the water place was divided into freshwater and saltwater. The distance to the waterfront was categorised by multiplications of 1.75 km; this was based on the side length of the square when every area defined by a postal code was hypothesised to be square-shaped. The distribution of patients was compared between the groups using the exact Wilcoxon rank-sum test.

![Distance from residential place to the nearest waterfront. Histograms showing the number of patients hierarchised by the distance from the residential place at disease onset to the nearest waterfront. The distance was categorised by multiplication of 1.75 km. Zone 0 covers the distance from 0 to 1.75 km, while Zone 1 covers the distance from 1.75 to 3.50 km. *P* values were calculated by exact Wilcoxon rank-sum test. (A) Distance to any waterfront. (B) Distance to seawater. (C) Distance to freshwater (river, lake or pond).](rmdopen-2020-001202f02){#F2}

Other statistical analyses {#s6-s4}
--------------------------

Continuous variables are shown as the median and 2.5--97.5 percentile, and were compared by the Kruskal--Wallis test. Categorical variables were compared by Fisher's exact test. Kaplan--Meier analysis was used for survival analysis, and equality of survival curves was tested using the Breslow test. All statistical analyses were performed using R 3.3.2 statistical software (<http://cran.r-project.org>).

RESULTS {#s7}
=======

Patient characteristics {#s7-s1}
-----------------------

In this study, 365 and 481 patients were eligible for seasonal and geographical analysis, respectively. We then divided the patients into three groups: (1) anti-MDA5 antibody-positive patients, (2) anti-ARS antibody-positive patients and (3) patients negative for anti-MDA5 or anti-ARS antibody. Two patients with anti-MDA5 and anti-ARS antibodies together were excluded. As shown in [table 1](#T1){ref-type="table"}, anti-MDA5-positive patients were younger at disease onset, had shorter disease duration and were predominantly CADM, compared with anti-ARS-positive patients or anti-MDA5-/ARS-negative patients. In terms of initial symptoms, skin eruption was more frequent than respiratory symptoms in anti-MDA5-positive patients, whereas respiratory symptom was the most common initial symptom in anti-ARS-positive patients. Muscle symptom was infrequent in all three groups, and its frequency was the greatest in anti-MDA5-/ARS-negative patients. At diagnosis, serum creatine kinase level was lower and ferritin level was higher in anti-MDA5-positive patients than other two patient groups, while KL-6 was higher in anti-ARS-positive patients than others. Six-month survival rates were the lowest in anti-MDA5-positive patients, in whom approximately one-third died. There was no heterogeneity in demographic and clinical features, including initial symptoms as well as 6-month survival rates, between patients used for the seasonal analysis and the geographical analysis ([table 1](#T1){ref-type="table"}).

###### 

Baseline characteristics and 6-month survival of patients included in seasonal and geographical analysis, stratified by myositis-specific autoantibodies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                   Seasonal analysis (n=365)   Geographical analysis (n=481)                                                                                           
  --------------------------- --------------------------- ------------------------------- ------------------- -------- ------------------ ------------------- ------------------- --------
  Demographics                                                                                                                                                                    

   Age at onset, years        55 \[29--78\]               59 \[29--78\]                   63 \[33--84\]       \<0.01   56 \[30--80\]      56 \[27--78\]       61 \[30--83\]       0.01

   Male                       64 (39%)                    35 (29%)                        30 (38%)            0.22     70 (35%)           45 (27%)            46 (39%)            0.10

   Disease duration, months   2 \[0--12\]                 3 \[0--23\]                     3 \[0--21\]         \<0.01   2 \[0--21\]        3 \[0--95\]         3 \[0--73\]         \<0.01

  Initial symptoms                                                                                                                                                                

   Skin eruption              93 (56%)                    16 (13%)                        36 (46%)            \<0.01   112 (56%)          21 (13%)            48 (41%)            \<0.01

   Respiratory symptoms       34 (20%)                    62 (52%)                        15 (19%)            \<0.01   41 (21%)           79 (48%)            28 (24%)            \<0.01

   Fever                      21 (13%)                    13 (11%)                        10 (13%)            0.91     24 (12%)           19 (12%)            12 (10%)            0.92

   Arthralgia                 12 (7%)                     9 (8%)                          3 (4%)              0.56     11 (6%)            12 (7%)             6 (5%)              0.74

   Muscle symptoms            4 (2%)                      8 (7%)                          12 (15%)            \<0.01   6 (3%)             15 (9%)             16 (14%)            \<0.01

   Others                     2 (1%)                      12 (10%)                        3 (4%)              \<0.01   6 (3%)             18 (11%)            7 (6%)              0.01

  Diagnosis                                                                                                                                                                       

   PM                         2 (1%)                      28 (23%)                        15 (19%)            \<0.01   2 (1%)             45 (27%)            28 (24%)            \<0.01

   Classic DM                 32 (19%)                    46 (38%)                        36 (46%)                     43 (22%)           63 (38%)            47 (40%)            

   CADM                       132 (80%)                   46 (38%)                        28 (35%)                     155 (78%)          56 (34%)            42 (36%)            

  Serum biomarkers                                                                                                                                                                

   CRP, mg/dL                 1.0 \[0.0--5.6\]            0.8 \[0.0--21.6\]               0.4 \[0.0--26.3\]   0.08     0.9 \[0.0--5.7\]   0.8 \[0.0--20.1\]   0.4 \[0.0--20.3\]   0.02

   CK, IU/L                   147 \[33--3209\]            419 \[31--4142\]                414 \[48--7505\]    \<0.01   140 \[25--2925\]   410 \[32--4165\]    337 \[36--9378\]    \<0.01

   KL-6, U/mL                 766\                        954\                            669\                0.01     757\               947\                646\                \<0.01
                              \[284--2491\]               \[202--5074\]                   \[207--10 257\]              \[263--2402\]      \[224--5074\]       \[176--6587\]       

   Ferritin, ng/mL            670 \[24--6783\]            223 \[10--2386\]                186 \[26--4808\]    \<0.01   668 \[32--6420\]   191 \[11--2278\]    210 \[23--3766\]    \<0.01

   6-month survival rates     67%                         98%                             96%                 \<0.01   68%                99%                 97%                 \<0.01
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Continuous variables are shown as the median \[2.5--97.5 percentile\]. Categorical variables are shown as n (%). The p-value for diagnosis was calculated by Fisher's exact test for a 3×3 table. Disease duration means duration from symptom onset to disease diagnosis. Initial symptoms were classified into skin eruption (ie, specific and non-specific skin lesions, and itch), respiratory symptoms (ie, cough and dyspnoea), fever, joint symptoms (ie, arthritis and arthralgia), muscle symptoms (ie, weakness and myalgia) and others. Six-month survival was calculated by the Kaplan--Meier method.

ARS, aminoacyl tRNA synthetase; CADM, clinically amyopathic dermatomyositis; CK, creatine kinase; CRP, C reactive protein; DM, dermatomyositis; KL-6, Krebs von den Lungen-6; MDA5, melanoma differentiation-associated gene 5; PM, polymyositis.

Seasonal analysis {#s7-s2}
-----------------

In the overall population, seasonality was not statistically significant (*p*=0.10). [Figure 1](#F1){ref-type="fig"} shows rose diagrams in individual MSA groups. In anti-MDA5-positive patients, the month of disease onset was not randomly distributed and peaked in January with an epidemic period between October and March (*p*=0.03). The seasonal analysis in anti-MDA5-positive patients was additionally carried out each year starting from October 2010 ([online Supplemental figure 3](#SP1){ref-type="supplementary-material"}). There were some variations in the seasonality depending on the year, but the number of patients was too small to conduct statistical analysis year by year. In contrast, seasonality was not detected in anti-ARS-positive patients or anti-MDA5-/ARS-negative patients. Thirty-two patients with anti-Jo-1 antibody were investigated separately, but again, there was no seasonality.

Geographical analysis {#s7-s3}
---------------------

A representative Google Map image of the residence of patients with PM-/DM-associated ILD is shown in [online supplemental figure 4](#SP1){ref-type="supplementary-material"}. As shown in [figure 2A](#F2){ref-type="fig"}, the residence of anti-MDA5-positive patients was significantly closer to any major waterfront than that of anti-ARS-positive patients or anti-MDA5-/ARS-negative patients (*p*=0.003 and 0.006, respectively). When the waterfront was restricted to seawater, a significant difference was lost ([figure 2B](#F2){ref-type="fig"}). In contrast, the distance from patient residence to freshwater was significantly different between anti-MDA5-and anti-ARS-positive patients or anti-MDA5-/ARS-negative patients (*p*\<0.001 and 0.005, respectively) ([figure 2C](#F2){ref-type="fig"}). There was no difference in the distance between the anti-ARS-positive and anti-MDA5-/ARS-negative groups.

Clinical characteristics of patients stratified by season and residence at disease onset in anti-MDA5-positive patients {#s7-s4}
-----------------------------------------------------------------------------------------------------------------------

We further examined potential differences in clinical presentation among four patient groups stratified by season and residence at disease onset: disease onset in either April--September or October--March and residing either close to freshwater (≤1.75 km) or far from freshwater (\>1.75 km) in anti-MDA5-positive patients. When clinical characteristics were compared among the groups, there were no statistically significant differences except for fever as the initial symptom, which was more frequent in patients who developed the disease in October--March and resided in the place close to freshwater ([online supplemental table 1](#SP1){ref-type="supplementary-material"}). There was no statistically significant difference in cumulative survival rates between the four groups ([online supplemental figure 5](#SP1){ref-type="supplementary-material"}).

DISCUSSION {#s8}
==========

In this study, we have demonstrated that anti-MDA5-associated ILD occurs predominantly from October to March in individuals residing near freshwater, although there was no difference in clinical presentation in patient groups stratified by season or residence at disease onset. This finding suggests that environmental triggers may play roles in eliciting anti-MDA5-associated ILD. Of the many potential environmental factors that may be associated with the onset of PM/DM, infection could be a plausible explanation for this time-space clustering at disease onset.^[@R4]^ In this regard, it has been recognised that some infectious agents can be transmitted by vectors inhabiting near freshwater, whose activity depends on the season, such as mosquitos and migratory birds,^[@R15]^ although it is just a hypothesis of potential environmental factors related to anti-MDA5-associated ILD. On the other hand, recognition of viral RNA by MDA5 initiates activation of NF-κβ and production of type I interferon (IFN) and other proinflammatory cytokines.^[@R17]^ In fact, several inflammatory cytokines, IL-6, IL-8, IL-18, IFN-α, IFN-γ, TNF-α and IP-10, were upregulated in the circulation of patients with anti-MDA5-associated ILD.^[@R18]^ The simultaneous onset of DM rashes and ILD with or without skeletal muscle involvement in anti-MDA5-positive patients might be explained by triggering onset by infection through the respiratory tract. MDA5 is known to recognise RNA viruses, including picornavirus (eg, Coxsackievirus), paramyxovirus, reovirus, dengue virus and West Nile virus.^[@R20]^ Interestingly, coronaviruses that cause acute respiratory distress syndrome have mechanisms circumventing the innate antiviral response mediated by MDA5.^[@R22]^ In fact, high serum concentrations of inflammatory cytokines and chemokines were detected in both anti-MDA5-associated ILD^[@R18]^ and acute respiratory insufficiency caused by infection with severe acute respiratory syndrome/Middle Eastern respiratory syndrome coronaviruses^[@R23]^ and even COVID-19.^[@R25]^ It is a future task to examine whether preceding virus infection contributes to the onset of rapidly progressive anti-MDA5-associated ILD.

This study has several limitations. First, disease onset was defined by any symptom potentially related to PM/DM, while previous studies examining seasonal clustering of PM/DM onset considered muscle weakness as disease onset.^[@R6]^ This may be one of the reasons for the lack of seasonal clustering in anti-ARS-positive patients in this study. Incidentally, more than half of the patients enrolled in JAMI lacked muscle symptoms. Second, the reliability of history taking is a matter of concern. In this regard, in the JAMI cohort, the median disease duration at diagnosis was only 2 months,^[@R12]^ which was much shorter than other studies, resulting in an improbable role of recall bias. Finally, it was difficult to examine environmental triggers related to residence at disease onset. This is a common problem in environmental factor research.^[@R27]^ Detailed behaviour monitoring before disease onset might be critical but appears impractical.

In conclusion, we found seasonal and geographical clustering at the onset of anti-MDA5-associated ILD. This might promote further studies investigating environmental triggers of this devastating condition.

###### Key messages

What is already known about this subject
----------------------------------------

-   Some disease subsets of polymyositis/dermatomyositis defined by myositis-specific autoantibodies showed seasonal patterns of disease onset.

What does this study add
------------------------

-   The onset of anti-MDA5-associated interstitial lung disease is influenced by the season and place of residence.

How might this impact clinical practice or future developments
--------------------------------------------------------------

-   Further studies investigating the environmental triggers of anti-MDA5-associated interstitial lung disease may provide useful clues for aetiology.
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